During the past few decades, the incidence of thyroid cancer has increased substantially in
many countries, including the USA. The rise in incidence seems to be attributable both to the …

Anaplastic thyroid carcinoma (ATC) is a rare malignancy, accounting for 1–2% of all thyroid
cancers. Although rare, ATC accounts for the majority of deaths from thyroid carcinoma. ATC …

The mitogen-activated protein kinase (MAPK) signaling pathway is the primary regulatory
module of various cellular processes such as cell proliferation, differentiation, and stress …

Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the American Thyroid Association's …

Purpose To investigate the prognostic value of the BRAF V600E mutation and the recently
identified TERT promoter mutation chr5: 1,295,228 C> T (C228T), individually and in their …

Thyroid cancer is a common endocrine malignancy. There has been exciting progress in
understanding its molecular pathogenesis in recent years, as best exemplified by the …

The 2013 discovery of Telomerase reverse transcriptase (TERT) promoter mutations chr5,
1,295,228 C> T (C228T) and 1,295,250 C> T (C250T) in thyroid cancer represents an …

Purpose To investigate the prognostic value of BRAF V600E mutation for the recurrence of
papillary thyroid cancer (PTC). Patients and Methods This was a retrospective multicenter …

Background About half of patients with papillary thyroid cancer have tumours with activating
BRAF V600E mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for …

Importance BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its
role in PTC-related patient mortality has not been established. Objective To investigate the …